

Pharmacology Lecture - 1

General Pharmacology
Primary Exam Teaching

Pharmacokinetics and Pharmacodynamics


- Volume of distribution - the relationship between the amount of drug in the body to the concentration of the drug found solely in plasma
 - $V_d = \text{Amount of drug in body} / \text{Concentration}$
- The V_d is an apparent volume and can exceed any physical volume found in the body because it is the volume necessary to contain the drug homogeneously at the concentration found.
- High V_d = higher concentration in extravascular tissues than vascular tissues e.g. fluoxetine, digoxin, verapamil
- Low V_d = contained within vascular compartment and their V_d is as close as possible to vascular volume e.g. aspirin, amoxicillin

Clearance

- Clearance - rate of elimination in relation to drug concentration
 - $CL = \text{rate of elimination} / \text{concentration}$
- Major sites of elimination are renal and liver
 - Renal excretion = excretion of unchanged drug
 - Liver excretion = biotransformation OR excretion of unchanged drug into bile

Clearance

- Rate of elimination is directly proportional to concentration - FIRST ORDER ELIMINATION - when clearance is first order it can be estimated as area under the curve
- When a constant amount of drug is eliminated per unit of time - ZERO ORDER ELIMINATION



Clearance

- For most drugs when concentration becomes high enough the elimination will be saturated and will be fixed, independent of concentration e.g. Ethanol, Phenytoin and Aspirin
- Rate of elimination = $V_{\max} \times C / K_m + C$
 - V_{\max} = maximum elimination capacity
 - K_m = drug concentration at which the rate of elimination is 50% of V_{\max}
 - At concentrations that are high relative to the K_m the elimination rate is almost independent of concentration

Clearance

- Half Life - the TIME required to change the concentration of the drug in the body by one half
- Flow dependent elimination - Some drugs will be largely eliminated on the first pass of the drug through the organ - hence the elimination of the drug will primarily depend on rate of delivery to the organ - these drugs are called HIGH EXTRACTION DRUGS e.g. lignocaine, propranolol

Bioavailability

- Definition: The amount of unchanged drug reaching the systemic circulation following administration by any route.
- IV administration = 100%
- May be less than 100% for 2 reasons
 - EXTENT OF ABSORPTION - lack of absorption from the GIT system
 - RATE OF ABSORPTION
 - FIRST PASS METABOLISM - Following absorption through the gut portal blood goes to the liver prior to systemic circulation.
 - These drugs can be metabolised in the gut wall as well as in the liver and this reduces bioavailability
 - Extraction ratio quantifies this degree of metabolism = $\text{Liver clearance} / \text{Liver blood flow}$
 - Drugs with high extraction ratios will show marked variations in bioavailability between subjects because of difference in hepatic function and blood flow.
 - Morphine, propranolol, verapamil, TCA - higher concentrations if blood is shunted past the liver
 - Phenytoi, diazepam, warfarin - have low extraction ratios
- Sublingual, Transdermal and Rectal route bypass first pass metabolism

Dosing

- Maintenance dose - Drug dosing in such a way as to maintain a steady state of drug in the system and thus replace the drug excreted since the preceding dose
 - equals the rate of elimination
 - dosing rate = clearance rate x target concentration
- Loading dose - When time to reach steady state is appreciable - a loading dose may be used to promptly raise plasma concentration
 - $L_d = V_D \times \text{Target Concentration}$

Biotransformation

- Transforms lipophilic drugs are made more polar and water soluble and hence their excretion is enhanced
- PHASE ONE and PHASE TWO reactions
 - PHASE ONE: Convert the drug into a more polar metabolite by introducing a functional group
 - aromatic hydroxylation, epoxidations
 - PHASE TWO: If phase one metabolites are sufficiently polar they may be readily excreted
 - Normally they need to undergo a reaction where an endogenous substance combines with this new functional group to create a highly polar molecule e.g. glucuronic acid, sulphuric acid

Biotransformation

- Biotransformation reactions occur in the GIT, Lungs, Skin, Kidney and Liver

PHASE 1 reactions

- Microsomal oxidation and Phase one reactions
 - Two key enzymes
 - P450 reductase
 - Cytochrome p450 (CYP3A4 is the most important one)
 - Enzyme induction - some of these chemically dissimilar p450 drugs, on repeated administration, induce p450 by enhancing the rate of its synthesis or reducing the rate of its degradation.
 - This induction results in an acceleration of substrate metabolism and a decline in the action of the inducer substrate and co administered drugs
 - Enzyme inhibition - Certain drug substrates inhibit P450 enzyme activity

PHASE 2 reactions


- Conjugation reaction with an endogenous substance - the endogenous substances are highly polar molecules
- A lot of these substrates originate in the diet
- Certain conjugations may lead to the formation of reactive species

Pharmacodynamics

- Receptors - determine the quantitative relation between dose and response and are responsible for selectivity of a drug
- Most receptors are proteins, but can also be enzymes (dihydrofolate reductase inhibition with methotrexate), transport proteins (Na/K ATPase), Structural proteins such as tubulin (for colchicine).

Concentration Effect

- Responses to low dose of a drug usually increase in direct proportion to dose. As dose increases, response increment diminishes.
- $E = E(\text{max}) \times C / (C + EC50)$
 - E is the effect at concentration C
 - E max - maximal response
 - EC50 is the concentration of drug that produces 50% of maximal effect




A

Receptors and Effectors

- Sometimes receptor coupling is linearly related to an effect - but this is often not the case i.e. secondary enzymatic signals)
- SPARE RECEPTORS - Receptors are said to be spares for a given pharmacological response if it is possible to elicit a maximal response at a concentration of agonist that does not result in full receptor occupancy.
 - e.g. myocardial cells exhibit maximal inotropic response to catecholamines even when 90% of receptors are blocked by irreversible antagonists.

Agonists

- Agonist - a chemical that binds to a receptor and activates it to produce a biological response.
- Types of agonist
 - Endogenous and exogenous
 - Physiological agonist - creates the same response but binds a different receptor
 - Full agonists bind and produce a fully efficacious reaction at a receptor e.g. morphine
 - Partial agonists - buprenorphine, bind a receptor, but even at full receptor occupancy do not produce a fully efficacious reaction.
 - Inverse agonist - act on the same receptor but produce an opposite reaction



Antagonists


- Antagonists bind a receptor but do not activate the receptor
- Competitive antagonist - In the presence of a fixed concentration of agonist, increasing concentration of competitive antagonist progressively inhibit the agonist response and vice versa.
- Increases the agonist concentration required for a given response, shifting the dose response curve to the right

Competitive antagonism


- Two important clinical consequences
 - Degree of inhibition caused by competitive antagonist is related to the concentration of the antagonist and can be different from patient to patient depending on clearance
 - Clinical response depends on concentration of the agonist that is competing for receptor binding.

A

Competitive Inhibition

**B**

Noncompetitive Inhibition



Irreversible antagonists

- The antagonists bind via covalent mechanisms, after occupancy the number of receptor left may not be enough to generate a maximal response in the presence of an otherwise appropriate dose of antagonist.
- Advantage: Duration of action is independent of its own rate of elimination and more dependent on the rate of turnover of the receptors
- Disadvantage: In overdose, cannot overcome effects by giving more agonist
- E.g. phenoxybenzamine - alpha agonist

Allosteric Modulation

- Binding to a site on the receptor protein separate from the agonist binding site and thereby preventing receptor activation
 - eg. Benzodiazepine

